Use of oxygen-ozone therapy to improve the effectiveness of antibiotic treatment on infected arthroplasty: protocol for a superiority, open-label, multicentre, randomised, parallel trial.

Clinical Trial Infection control Orthopaedic & trauma surgery THERAPEUTICS

Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
04 Jan 2024
Historique:
medline: 5 1 2024
pubmed: 5 1 2024
entrez: 4 1 2024
Statut: epublish

Résumé

Surgical site infections still remain a major public health challenge and have become an increasing universal risk, especially for the implantation of orthopaedic devices.Unfortunately, the discovery and increasingly widespread use (especially the misuse) of antibiotics have led to the rapid appearance of antibiotic-resistant strains today; more and more infections are caused by microorganisms that fail to respond to conventional treatments.Oxygen-ozone therapy has been extensively used and studied for decades across various potential medical applications and has provided consistent effects with minimal side effects.This study aims to determine the superiority of oxygen-ozone therapy in combination with oral antibiotic therapy in patients with wound infections after an orthopaedic device implantation when compared with antibiotic therapy alone. This is an open-label, multicentre, randomised, parallel-group study that aims to assess the efficacy and safety of oxygen-ozone therapy in combination with oral antibiotic therapy to treat infections in patients (male or female aged ≥18 years) having undergone surgery for the implant of an orthopaedic device. Patients must have at least one (but no more than three) postoperative wounds in the site of surgery (ulcers, eschars and sores) and at least one symptom (pain, burning, redness and malodour) and at least one sign (erythema, local warmth, swelling and purulent secretion) of infection of at least moderate intensity (score ≥2) in the target lesion at the screening visit (patients with wounds without signs of localised infection or with undermining wounds will be excluded).Patients (n=186) will be recruited from five Italian hospitals and studied for 7 weeks. All will be assigned to one of the two treatment groups according to a web-based, centralised randomisation procedure and placed into either the (1) intervention: oxygen-ozone therapy 2-3 times a week for 6 weeks (for a maximum of 15 sessions) simultaneously with an appropriate oral antibiotic therapy prescribed at baseline or (2) control: oral antibiotic therapy prescribed at baseline.The primary outcome is the efficacy and superiority of the treatment (ozone and oral antibiotic therapies); secondary outcomes include the resolution of signs and symptoms, modifications in lesion size and the treatment's safety and tolerability. This study has been reviewed and approved by the responsible Independent Ethics Committee (IEC) of COMITATO ETICO CAMPANIA NORD, located at 'Azienda Ospedaliera San Giuseppe Moscati di Avellino'.After completion of the study, the project coordinator will prepare a draft manuscript containing the final results of the study on the basis of the statistical analysis. The manuscript will be derived by the co-authors for comments, and after revision, it will be sent to a major scientific journal. Findings will be disseminated via online and print media, events and peer-reviewed journals. NCT04787575.

Identifiants

pubmed: 38176866
pii: bmjopen-2023-076739
doi: 10.1136/bmjopen-2023-076739
doi:

Banques de données

ClinicalTrials.gov
['NCT04787575']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e076739

Informations de copyright

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Fidelia Cascini (F)

Department of Life Sciences and Public Health, Università Cattolica del Sacro Cuore, Rome, Italy.

Marianno Franzini (M)

Società Italiana di Ossigeno-Ozono Terapia (SIOOT), Gorle (BG), Italy.

Arnaldo Andreoli (A)

ASST Fatebenefratelli Sacco, Milano, Italy.

Alfonso Manzotti (A)

ASST Fatebenefratelli Sacco, Milano, Italy.

Chiara Cadeddu (C)

Department of Life Sciences and Public Health, Università Cattolica del Sacro Cuore, Rome, Italy.

Gianluigi Quaranta (G)

Department of Life Sciences and Public Health, Università Cattolica del Sacro Cuore, Rome, Italy.
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy.

Andrea Gentili (A)

Department of Life Sciences and Public Health, Università Cattolica del Sacro Cuore, Rome, Italy andrea.gentili1989@gmail.com.

Walter Ricciardi (W)

Department of Life Sciences and Public Health, Università Cattolica del Sacro Cuore, Rome, Italy.

Classifications MeSH